Experts in the field discuss new therapies and how they will impact the dermatologist's practice.

Peter Lio, MD: Innovations in JAK Inhibitors

April 12, 2022

Peter Lio, MD, of Medical Dermatology Associates of Chicago in Chicago, Illinois, discusses recent innovations in atopic dermatitis therapies with regard to JAK inhibitors. Dr. Lio discusses several new drugs in this class, including topical ruxolitinib, oral abrocitinib, and oral upadacitinib, and provides important guidance for practitioners treating their patients with these new therapies.


Raj Chovatiya, MD, PhD: Explaining the Mechanisms and Advantages of JAK Inhibitors

Raj Chovatiya, MD, PhD, Director of the Center for Eczema and Itch at the Department of Dermatology at Northwestern University Feinberg School of Medicine, discusses the newly available JAK inhibitors for use in a variety of dermatological conditions. Dr. Chovatiya reviews how JAK inhibitors work differently from other agents to reduce inflammation and the benefits that they can have for certain patient populations.

Read More